ACP-105

The neuroprotective SARM

Dosage

Acp-105 has been tolerated in mice in dosages up to 1mg/kg. As ACP-105 is relatively new in the world of SARMs dosages have been less reported in current scientific studies, however, with the limited information available an equivalent human dose of 10 mg per day is generally accpeted. ACP-105 has a shorter half-life compared to other SARMs, to maintain stable levels it has been used up to 3 times per day.

ACP-105 Benefits

ACP-105 has been used less frequently in research as oppose to other SARMs including Ostarine and Andarine so reported benefits and side effects are much less. ACP has the smallest molecular weight of all the SARMs. Like other SARMs' it has a high bioavailability. ACP-105 is reported to be much stronger than Ostarine or Andarine but has less supressive side-effects than either.

ACP-105 is also becoming recognized for improvement in mental clarity and well-being, having beneficial cognitive and nootropics effects.

Buy research chemical ACP-105 from USA here.

Buy research chemical ACP-105 from Canada here.

History

ACP-105 is a newer selective androgen receptor modulator (SARM) originally manufactured by Acadia. Acadia claims initial research of ACP-105 has had potent anabolic effects, most similar to testosterone. ACP-105, similarly to other SARM's, bind to the bodies androgen receptors and recode DNA to become more efficient. SARMs were originally developed as early as the 1940's (Ligand Pharmaceuticals) but took a developmental leap in the 1990's by GTx Inc. SARMs in research are recognized as safer alternatives to Anabolic Steroids as they have fewer side-effects.

---

ACP-105- Anabolic to Androgenic Ratio

ACP-105 has been found in research to have an anabolic: androgenic ratio of 3.19: 1. Other SARMs with similar ratios include Ostarine and S4.

Relevant Studies

Alzheimer's Disease

Low levels of testosterone and estrogren have been tied to increased risks for diseases including Alzheimer's. It has been determined that supplementation of these hormones can improve the cognitive decline found in patients with the disease. A study conducted in 2013 mimicked the effect of DHT by administering Selective Androgen Receptor Agonist ACP-105, alone or a combination of with the selective estrogen receptor β (ERβ) agonist AC-186 to male gonadectomized triple transgenic mice. Results of the study found that ACP-105 by itself decreases anxiety behaviors, and when combined with AC-186, it improved cognitive function.

George, S., Petit, G. H., Gouras, G. K., Brundin, P., & Olsson, R. (2013). Nonsteroidal selective androgen receptor modulators and selective estrogen receptor β agonists moderate cognitive deficits and amyloid-β levels in a mouse model of Alzheimer's disease. ACS chemical neuroscience, 4(12), 1537–1548. https://doi.org/10.1021/cn400133s

Effect on Prostate

A 2008 study was conducted to compare ACP-105 to exogenous testosterone in regards to hypogonadism, osteoporosis, CNS indications and muscle wasting conditions. ACP-105, in cell based assays, was found to be an extremely potent Selective Androgen Receptor agonist. In animal studies using castrated rats ACP-105 has demonstrated a potent ability to suppress the luteinizing hormone surge while having strong anabolic effects on the levator ani muscle. ACP-105 had minimal effects on the prostate's of castrated animals and no detectable effect on prostate of intact rats. ACP-105 behaves as a partial androgen receptor agonist, partially reversing the androgenic effect of exogenous testosterone. This study suggests ACP-105 may be a superior alternative to exogenous testosterone as it has strong anabolic effects very similar to testosterone on muscle mass, while maintaining minimal side effects on the prostate.

Bradley, S.R., Lameh, J., Schlienger, N., Whitten, K., Lewinsky, R., Badalassi, F., Pawlas, J., Tolf, B.-R., Bonhaus, D. and Piu, F. (2008), In vitro and in vivo profile of a novel tissue selective, orally bioavailable non-steroidal androgen receptor modulator (ACP-105). The FASEB Journal, 22: 670-670. https://doi.org/10.1096/fasebj.22.2_supplement.670

Disclaimer

All information found on vantanexcorp.com, and its associated blog is intended for informational and entertainment use only. Vantanex Corp does not provide medical advice. Vantanex Corp tries to provide the most recent and up-to-date research however can make no guarantees this is the case. Vantanex Corp does not condone the use of illegal drugs or the use of drugs for unintended purposes. Before taking any medication, over-the-counter drugs or medication, seek medical advice from a medical professional. No liability will be assumed for the use of these articles, the contained information is not medical advice.